Proven bacterial, viral, conjugate, and E.coli expression platforms support partners from discovery and process development to GMP readiness and clinical manufacturing ...

VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...

Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in ...

Lotte Biologics has teamed up with US biotech firm Asimov to unveil a next-generation contract development organization (CDO) ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site ...

WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programsQualified Vero Master Cell Bank and Wor ...

(NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; ...

VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a ...

Shilpa Biologicals launches PartnerPower, a proprietary platform for real-time visibility on process development: Our Bureau, Mumbai Tuesday, June 23, 2026, 12:45 Hrs [IST] Shilpa ...

An adenoviral process that works for one construct can fail with the next. A harvest step optimized in development can erode yield at scale, and an early analytical method can stall a program at ...

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of Deciparticle™ Technology for Hydrophobic Therapeutics ...

As pipelines across modalities diversify, regulatory scrutiny intensifies, and the margin for error in development execution continues to shrink, partnering with a CDMO has never been more critical.